Success Metrics

Clinical Success Rate

80.0%

Based on 4 completed trials

Completion Rate

80%(4/5)

Active Trials

0(0%)

Results Posted

50%(2 trials)

Terminated

1(20%)

Phase Distribution

Ph phase_2

40%

Ph phase_4

20%

Ph phase_3

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 2Efficacy & side effects

2(50.0%)

Phase 3Large-scale testing

1(25.0%)

Phase 4Post-market surveillance

1(25.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Terminated(1)

Detailed Status

Completed4

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

80.0%

Most Advanced

Phase 4

Trials by Phase

Phase 22 (50.0%)

Phase 31 (25.0%)

Phase 41 (25.0%)

Trials by Status

completed480%

terminated120%

Recent Activity

0 active trials

Showing 5 of 5

completed

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

NCT02600741

completedphase_4

Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients

NCT02307396

terminatedphase_3

Clinical Trials (5)

Showing 5 of 5 trials

NCT02600741

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

Completed

NCT02307396Phase 4

Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients

Completed

NCT02374567Phase 3

Pharmacovigilance in Gerontopsychiatric Patients

Terminated

NCT00929578Phase 2

Fluphenazine Hydrochloride for Psoriasis

Completed

NCT02203786Phase 2

D1 and D2 Dopamine Receptors in Gambling and Amphetamine Reinforcement

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5